$14.530
-0.080 (-0.55%)At close
LYEL News
LYEL Events
Lyell Cash and Securities Balance at $228M
Cash, cash equivalents and marketable securities as of June 30, 2026 were $228M compared to $247.2M as of December 31, 2025. Lyell believes that its current cash, cash equivalents and marketable securities balances will be sufficient to meet working capital and capital expenditure needs into the third quarter of 2027.
Lyell Immunopharma Files to Sell 1.1M Shares of Common Stock
Lyell Immunopharma files to sell 1.1M shares of common stock for holders
AbCellera Appoints Lynn Seely as Independent Director
AbCellera (ABCL) announced the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. Dr. Seely currently serves as president and CEO of Lyell Immunopharma (LYEL).
Lyell Immunopharma Closes $50M Share Sale
Lyell Immunopharma closed the sale of an additional $50M of shares of its common stock to investors from its July 2025 equity private placement of up to $100M, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel in patients with relapsed/refractory large B-cell lymphoma in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026. Most recently, she operated as an independent CFO and CBO consultant, providing strategic guidance to multiple life sciences organizations.
Lyell Immunopharma Begins PiNACLE - H2H Phase 3 Trial
Lyell Immunopharma announced that the first patient has been dosed in the PiNACLE - H2H Phase 3 trial evaluating rondecabtagene autoleucel compared to lisocabtagene maraleucel or axicabtagene ciloleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma receiving treatment in the second-line setting. "Data from Lyell's single-arm pivotal PiNACLE trial in patients with later-stage large B-cell lymphoma are expected to be submitted for marketing approval to the FDA next year," said David Shook, MD, Lyell's Chief Medical Officer. "We are now pleased to have underway PiNACLE - H2H, the first-of-its-kind Phase 3 head-to-head randomized controlled CAR T-cell trial. This strategy demonstrates Lyell's confidence in ronde-cel's potential to be the best-in-class CAR T-cell treatment for patients with relapsed or refractory disease."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。